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Inhibition of CDK9 as a therapeutic 
strategy for inflammatory arthritis
Annelie Hellvard1,2, Lutz Zeitlmann3, Ulrich Heiser4, Astrid Kehlen4, André Niestroj4,  
Hans-Ulrich Demuth3,4, Joanna Koziel5, Nicolas Delaleu1,  Jan Potempa5,6 & Piotr Mydel1,7
Rheumatoid arthritis is characterised by synovial inflammation and proliferation of fibroblast-
like synoviocytes. The induction of apoptosis has long been proposed as a target for proliferative 
autoimmune diseases, and has further been shown to act as a successful treatment of experimental 
models of arthritis, such as collagen-induced arthritis. Here we examined the effects of specific oral 
small-molecule inhibitors of the transcription regulating cyclin-dependent kinase 9 on the development 
and progression of collagen-induced arthritis. DBA/1 mice were immunised with bovine collagen type 
II and treated orally with specific CDK9 inhibitors. The effects of CDK9 inhibition on RNA levels and 
protein expression, apoptosis induction, caspase activation and lymphocyte phenotype were further 
analysed. Mice showed a significant delay in disease onset and a reduction in disease severity following 
treatment with CDK9 inhibitors. Inhibiting CDK9 activity in peripheral blood mononuclear cells resulted 
in the loss of Mcl-1 expression at both the protein and RNA levels, along with a subsequent increase 
in apoptosis. CDK9 specific inhibitors may be a potential alternative treatment not only of cancer, but 
also for autoimmune- and inflammatory diseases. Taken together, these results show that transient 
inhibition of CDK9 induces apoptosis in leukocyte subsets and modulates the immune response.
The hallmark of RA is inflammation of the joints due to autoimmune reactions, which over time cause irreversi-
ble damage to both cartilage and bone. Despite the high influx of inflammatory cells into RA joints and synovial 
hyperplasia, only low levels of apoptosis are observed1,2. This apparent dysregulation of apoptosis may enable 
autoreactive cells to survive and/or fail to control the number of activated effector cells, thereby promoting the 
development of autoimmune conditions3. Synovial fluid, synovial fibroblasts, and macrophages from RA patients 
express high levels of anti-apoptotic Bcl-2 family proteins4,5, and synovial fluid from RA patients protects neu-
trophils from apoptosis in vitro due (at least in part) to the presence of accumulated pro-inflammatory mediators 
and anti-apoptotic stimuli within the fluid1.
Recently, small-molecule inhibitors of cyclin-dependent kinases (CDKs) has been tested for their ability to 
induce apoptosis. CDKs are enzymes that, together with their cyclin subunits, regulate cell cycle progression 
(CDK1, 2, 4, and 6) and transcription (CDK7 and 9). Small-molecule compounds such as flavopiridol and ros-
covitine inhibit a number of different CDKs (CDK1, 2, 4, 6, 7, and 9 and CDK2, 5, 7, and 9, respectively)6,7, and 
various inhibitors are undergoing phase II clinical trials for the treatment of cancer. Initially, CDK inhibitors were 
thought to regulate proliferative diseases by inhibiting cell cycle-regulating CDKs, thereby inducing cytostasis. 
However, recent studies show that the most potent treatments (i.e., those that target CDK9) induce high levels of 
apoptosis in cancer cell lines8,9. CDK inhibitors have been used to treat inflammatory diseases in an attempt to 
address the over-proliferation of immune cells and fibroblasts. Treatment with the non-specific CDK inhibitor, 
roscovitine, induces neutrophil apoptosis by down-regulating Mcl-1 and activating caspases10. The pro-apoptotic 
effect of non-specific CDK inhibitors is mediated through inhibition of CDK9, which increases apoptosis by 
reducing the expression of pro-inflammatory proteins such as Mcl-1 and XIAP8,11,12.
Inhibition of CDK9 has a significant impact on proteins with short half-lives, e.g., anti-apoptotic proteins such 
as Mcl-1, which has a half-life of only a few hours11,13. Both roscovitine10 and flavopiridol14 are effective treatments 
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for murine arthritis. However, because neither of these compounds discriminates between CDKs involved in the 
cell cycle and those involved in transcriptional regulation, these studies did not examine the ability of CDK9 to 
inhibition transcription or its subsequent effect on apoptosis.
Targeting CDK9 is a novel method of controlling immune responses without affecting the cell cycle. 
Garcia-Cuellar et al. recently showed that the CDK9 inhibitors PC585 and PC579 are efficient suppressors of 
mixed-lineage leukemia proliferation and that CDK9 inhibition increase the survival in a murine mixed-lineage 
leukemia model15. However, no study has yet examined whether specific CDK9 inhibitors have an effect on RA. 
Therefore, the aim of the present study was to examine the effects of two highly specific CDK9 inhibitors in a 
murine model of collagen-induced arthritis (CIA).
Results
Characterisation of a potent, selective inhibitor of CDK9. The two compounds (PC585 and PC579) 
used in the present study are specific inhibitors of CDK915. Tests showed that neither compound had a significant 
inhibitory effect on any of 235 kinases examined when used at a concentration of 1 μ M (data not shown).
Administration of CDK9 inhibitors in murine arthritis models. Daily treatment with CDK9 inhib-
itors (PC585 and PC579; each at 10 mg/kg) had a marked impact on CIA development, progression, and sever-
ity in DBA/1 mice. We compared the effects of the two orally dosed CDK9 inhibitors with those of Enbrel (a 
recombinant human TNF receptor p75 Fc fusion protein commonly used to treat RA). Treatment with the CDK9 
inhibitors resulted in a significant delay in disease onset. The first clinical signs of arthritis presented in control 
animals on Day 26, whereas animals treated with PC585 showed the first symptoms on Day 31 (p = 0.02). The 
effect of PC585 was comparable with that of Enbrel (p = 0.008; Fig. 1A). Treatment with PC579 did not cause a 
significant delay in disease onset; however, we observed a 30% reduction in disease incidence (compared with 
the control) at the end of the experiment (Fig. 1A). The clinical score for the control group increased rapidly up 
until Day 39, reaching a mean arthritis index of 4.15. By contrast, mice treated with PC585 or PC579 showed a 
mean arthritis index of 0.7 and 1.35, respectively (Fig. 1B). Animals treated with Enbrel showed comparatively 
few clinical symptoms and a mean arthritis index of 0.6 (Fig. 1B). Morphological examination of joint tissues 
confirmed that the CDK9 inhibitors prevented the clinical signs of CIA. When compared with that in the control 
group, inflammatory cell infiltration and/or thickening of the synovial membrane was markedly reduced in both 
treatment groups (Fig. 1C,F). In addition, the level of cartilage and bone destruction was significantly reduced 
in all treatment groups (PC585, p < 0.01; PC579, p < 0.05; Enbrel, p < 0.01) (Fig. 1D,F). Interestingly, inhibitor 
treatment had no impact on the level of anti-collagen type II (CII) antibodies (Fig. 1E).
CDK9 inhibition results in the loss of Mcl-1 expression by inflammatory cells. Non-specific CDK 
inhibitors impact cell survival by inducing apoptosis and by down-regulating expression of the anti-apoptotic 
protein, Mcl-110; however, there is no direct evidence to suggest that the mechanism(s) underlying these phenom-
ena is mediated solely by CDK9. Western blot analysis of protein extracts from the spleens of arthritic animals 
treated only twice weekly with PC585 (30 mg/kg and 10 mg/kg, respectively) revealed that Mcl-1 expression was 
down-regulated in a dose-dependent manner. Notably, there was an increase in expression of the pro-apoptotic 
isoform, Mcl-1s (Fig. 2A). Immunohistochemical analysis of joints from CIA mice showed that Mcl-1 expres-
sion was very low in treated animals compared with that in untreated controls. The latter showed signs of active 
inflammation and high expression of Mcl-1 (Fig. 2B). We further analysed Mcl-1 expression in PBMC activated 
with anti-CD3 in vitro. Treatment with CDK9 inhibitors led to reduced Mcl-1 expression as manifested by the 
lack of Mcl-1 protein after 6 h and 24 h (Fig. 2C). This was confirmed by reverse transcriptase PCR analysis, which 
showed that inhibition of CDK9 abrogated transcription of Mcl-1 (data not shown).
Taken together, these results show that specific inhibition of CDK9 in several cell types prevents the transcrip-
tion of Mcl-1 and reduces its expression in peripheral lymphoid organs and disease target tissue.
Inhibiting CDK9 induces apoptosis via a “hit-and-run” mechanism. As described above, treatment 
with CDK9 inhibitors led to a reduced expression of the anti-apoptotic protein Mcl-1. Therefore, we next exam-
ined the apoptotic effects of CDK9 inhibitors by staining PBMCs with Annexin V and 7AAD. Incubation with 
10 μ M PC585 induced apoptosis in PBMC to the same extent as staurosporine (2 μ M) at 12 h (Fig. 2D). The 
mean percentage of Annexin V+ cells was 20.13% in non-treated cells and 38.28% in CDK9 inhibitor-treated 
cells (Fig. 2D; p < 0.0001). It is worth noting that the CDK9 inhibitors used in this study have a relatively short 
half-life (2 h) in plasma; therefore, to investigate whether short-term exposure is sufficient to induce the irreversi-
ble changes that lead to apoptosis, we exposed cells to 10 μ M PC585 for 3 h or 6 h. The inhibitor was then removed 
and the number of Annexin V+ cells analysed at various time points thereafter. Compared with that in untreated 
controls, Annexin V expression by inhibitor-treated cells increased slightly at 3 h (Fig. 2E). The percent of apop-
totic cells in the control samples only increased marginally up to 30 h when it reached 15.22%. By contrast, the 
rate of apoptosis in PBMCs treated for 3 h with PC585 increased; more than 30% of cells were Annexin V+ after 
30 h (Fig. 2E). When cells were pre-incubated with PC585 for 6 h, 80.8% remained viable and non-apoptotic up 
until the point at which the inhibitor was removed. The number of apoptotic cells increased nearly 2-fold during 
the first 12 h following inhibitor removal, and continued to increase thereafter (42.8% of cells were Annexin V+ 
after 30 h). By contrast, only 17.65% of control cells were Annexin V+ (Fig. 2F).
CDK9 inhibition increases the regulatory T cell population. To further examine the impact of inhib-
itor treatment on the immune system, we harvested splenocytes at the end of the prophylactic experiment. Flow 
cytometric analysis showed that the percentage of regulatory T cells (Tregs; CD4+CD25+Foxp3+) in spleens from 
arthritic mice receiving daily inhibitor treatment was significantly higher than that in control mice, even though 
the overall CD4+ population remained unchanged (Fig. 3A–C). This increase in the Treg cell population was not 
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observed in mice receiving anti-TNF treatment. Therefore, we next treated healthy animals with 10 mg/kg of 
PC585 for 7 days to examine whether the CDK9 inhibitors triggered the increase in Treg cells. The results showed 
that the Treg cell population in the spleens of treated animals was much higher than that in non-treated healthy 
controls (3D).
CDK 9 treatment prevents down-regulation of Del-1 expression in endothelial cells. Leukocyte 
migration/extravasation and angiogenesis are important for the pathogenesis of RA; thus, they are interesting tar-
gets for drug development. Previous studies suggest that an endogenous leukocyte-endothelial inhibitor (called 
developmental endothelial locus-1; Del-1) plays a role in adhesion and leukocyte migration16 and apoptosis17, 
thereby contributing to the development of inflammatory diseases. Thus, we next examined the expression of 
Del-1 in the joints of CDK9 inhibitor-treated CIA mice and corresponding controls. Del-1 expression in synovial 
tissue was restricted to endothelial cells, although the protein was also detected in extravascular areas (proba-
bly due to diffusion from epithelial cells) (Fig. 4). We also found that Del-1 co-localized with neutrophils pres-
ent in the joint tissue. There was a significant reduction in the expression of Del-1 protein in inflamed tissues, 
confirming the finding of Choi et al.16 (Fig. 4B,C). Interestingly, the levels of Del-1 were higher in joint tissues 
(endothelium and the perivascular areas) from mice treated with the CDK9 inhibitors (PC585 and PC579) than 
in non-treated animals (Fig. 4E,F). This suggests that treatment with CDK9 inhibitors leads to maintained Del-1 
expression in endothelial cells, which might contribute to protection against RA by limiting LFA-1-mediated 
neutrophil trafficking to inflamed tissues.
Figure 1. Treatment with CDK9 inhibitors ameliorates collagen induced arthritis. (A) Kaplan-Meier 
plots showing onset of arthritis during treatment with 10 mg/kg CDK9 inhibitors (PC585, n = 10 and PC579 
n = 10), 100 ug anti-TNF treatment (Enbrel, n = 10) or untreated controls (n = 10). (B) Development of clinical 
signs of arthritis during the course of experiment. (C) Histological evaluation of synovitis and (D) erosions 
in joints (Controls, n = 10; PC585, n = 10; PC579, n = 9; Enbrel, n = 9). (E) Serum levels of IgG fraction of 
antibodies against CII at end of experiment (Controls, n = 10; PC585, n = 10; PC579, n = 9; Enbrel, n = 9). 
(F) Representative histological changes in the front paw joints of animals treated with PC585 and non-treated 
controls. Horizontal line and error bars represent the mean and SEM, respectively. Box and whiskers graphs 
show median and min to max values. Differences between groups were analyzed using log-rank test, two-way 
ANOVA or one-way ANOVA with Bonferronion post-test. * p < 0.05; * * p < 0.01; * * * p < 0.001; * * * * p < 0.0001.
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Short-term exposure to CDK9 inhibitor leads to transient transcriptional effects in vivo. ID 
family proteins regulate cell proliferation, differentiation, and angiogenesis, and their expression is up-regulated 
Figure 2. Specific CDK9 inhibitor affects apoptosis by inhibition of Mcl-1 expression. (A) Mcl-1 western 
blot on protein extract from splenocytes of arthritic mice undergoing treatment with PC585 and control. 
Row one and two were run on the same western blot. (B) Immunohistochemical staining for Mcl-1 of knee 
joint from CIA mice treated daily with 10 mg/kg of PC585 and control. (C) Western blot of protein extract of 
anti-CD3 activated PBMC treated with PC585 and non-treated control cells (D) Pro-apoptotic potential of 
10 μ M PC585 as compared to 2 μ M staurosporin. (E) PBMC were pre-incubated with PC585 for 3 h and (F) 
6 h followed by removal of PC585. One-way ANOVA with Bonferroni’s post-test was used for the statistical 
evaluation. * * * * p < 0.0001.
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in RA patients18. To determine the role of CDK9 in angiogenesis, we harvested blood and spleens from CIA mice 
at endpoint 1, 3 and 5 h after the final administration of PC585.
ID3, PNUTS and TNFα were used as biomarkers to monitor the in vivo transcriptional effects of CDK9 
inhibition. When analysed one hour after dosing, high exposure levels of PC585 correlated with inhibition of bio-
marker expression to 20–30% of normal levels. All three mRNAs returned to normal levels when analysed 3 or 5 h 
after dosing, correlating with reduced exposure of PC585. (Fig. 5A,B). Taken together, these data show that even a 
transient reduction in the levels of pro-inflammatory molecules has a profound downstream impact on the devel-
opment and progression of arthritis. Interestingly, when we examined the expression of VCAM-1 and ICAM-1 in 
PBMCs after short-term treatment with PC585 (a 3 h pre-incubation), we observed a striking down-regulation of 
integrin expression, which persisted after inhibitor wash-out (Fig. 5C,D).
Discussion
To date, treatments involving small-molecule inhibitors that target CDK are aimed to control the proliferation 
and expansion of cancer cells8,9. As more studies use CDK inhibitors to treat inflammatory diseases, the role 
of transcription-regulating CDKs in the resolution of inflammation has been increasingly acknowledged10,19. 
Although treating CIA with flavopiridol, which inhibits CDK1, 2, 4, 6, 7, and 9, has proven to be a successful 
approach14, we hypothesised that CDK9 is the key target of flavopiridol in the treatment of RA.
When we treated CIA mice with specific CDK9 inhibitors, we observed a marked improvement in the clinical 
signs of arthritis. Indeed, the extent of erythema and swelling was reduced to levels observed in mice treated 
with a TNF inhibitor. Immunohistochemical analysis of joints from control mice revealed high levels of Mcl-1 
expression; however, levels were significantly lower in the inhibitor-treated group. This is of particular interest 
because although Mcl-1 expression is normally tightly regulated, it is up-regulated in the joints of RA patients4,5. 
Compounds such as flavopiridol and roscovitine (and its more potent and selective analog, S-CR8) reduce the 
expression of Mcl-1 transcripts mainly by inhibiting CDK9-mediated phosphorylation of RNA polymerase II20. 
This prompted us to examine the levels of Mcl-1 in mice treated systemically with CDK9 inhibitors. Treated 
animals showed lower levels of splenic Mcl-1 expression than control animals, resulting in a shift towards a more 
pro-apoptotic environment. Studies show that the phosphatidylinositol 3-kinase (PI3-kinase)/Akt-1 and signal 
transducer and activator of transcription 3 (STAT3) pathways are essential for maintaining constitutive expres-
sion of Mcl-1 in macrophages4,21. CDK9 binds STAT3 upon IL-6 stimulation22; therefore, inhibiting CDK9 will 
impede the activation of this important inflammatory transcription factor, leading not only to a dampening of the 
inflammatory response but also a reduction in Mcl-1 expression.
When we examined the kinetics of apoptosis induction, we found that once cells had been exposed to a CDK9 
inhibitor, apoptosis continued after the inhibitor was removed. The percentage of apoptotic PBMCs increased 
1.71 and 2.45-fold relative to that in control cells after exposure to a CDK9 inhibitor for 3 h or 6 h, respectively. 
Figure 3. CDK9 inhibition increase percentage of splenic regulatory T cells. (A) Representative dot-plots 
of CD25 and Foxp3 expressing CD4+ T cells. (B) Flow cytometric analysis of Foxp3 and CD25 on T cells in 
splenocytes from arthritic mice treated daily with PC585 (n = 8), PC579 (n = 8) or Enbrel (n = 9) (Control, 
n = 10). (C) Percentage of CD4+cells in spleens of mice treated daily with PC585 (n = 8), PC579 (n = 7) or 
Enbrel (n = 9) (Control, n = 10) (D) CD4+ T cells expressing CD25 and Foxp3 in spleen of 10 healthy treated 
mice and 10 controls. Box and whiskers graphs show median and min to max values. Differences between two 
groups were analyzed using Mann-Whitney U test and One-way ANOVA with Bonferroni’s post-test was used 
for comparison between multiple groups. * * p < 0.01.
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Figure 4. CDK 9 inhibitors protect against inflammatory Del-1 down-regulation. Representative fluorescent 
confocal images of slides stained for Del-1 (B,C,F,G), Ly6G (D,H) and their sequential H&E sections (A,E). 
Images show knee joints from arthritic DBA/1 mice treated with CDK9 inhibitor PC585 at 10 mg/kg (E–H) and 
arthritic controls (A–D) at day 47 of CIA. Expression is limited to endothelial cells but can be also seen also in 
perivascular area (V) and PMNs (arrows).
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This effect lasted up to 30 h after the inhibitor was removed (the limit of the time-course measured), suggesting 
that a “hit-and-run” mechanism was in operation.
It is thought that RA is caused by a breakdown of self-tolerance, which in effect leads to an immune response 
against self-antigens. Under normal physiological conditions, Tregs cells maintain homeostasis by suppressing 
these autoimmune responses. Tregs protect against RA and other autoimmune diseases, although the underlying 
mechanism remains relatively unclear. Studies report conflicting results with respect to the number of Tregs cir-
culating in RA patients relative to that in controls23–25. Several studies have explored the possibility of using Tregs 
as a potential therapeutic target in RA. There has been studies showing that induction of collagen specific oral 
tolerance an increase in Tregs could be observed26,27. Induction of Tregs through usage of peptides28, antibodies29, 
and GM-CSF30, has been examined in murine models of autoimmunity resulting in a significant reduction in 
disease severity. Interestingly, we found that the percentage of Tregs (CD4+CD25+Foxp3+) in animals treated 
with CDK9 inhibitors was higher than that in controls. This increase was not associated with changes in disease 
severity, as healthy mice treated with PC585 displayed a similar increase in the Tregs population. Wang et al. 
has showed that CDK inhibitors induce apoptosis of neutrophils in the presence of GM-CSF, indicating that the 
survival signal received during inflammation is not strong enough to counteract the pro-apoptotic effect of CDK 
inhibition11. Further, in addition to promoting survival in granulocytes GM-CSF has a clear immunomodulatory 
effect through its induction of Treg development both directly via the GM-CSF receptor or via tolerogenic DCs 
and TGF-β 30,31. It has been proven that treatment with GM-CSF does expand the Treg population in vivo32 and 
that the presence of anti-GM-CSF antibodies may have a negative effect on inflammatory diseases such as Chron’s 
Disease33 Even though we could not identify an increase of GM-CSF in sera of inhibitor treated mice (data not 
shown), it may be possible that an increase of GM-CSF in local inflammatory foci or a downstream indirect effect 
could have caused an expansion of the Treg population.
A strong B cell response is activated in CIA mice, which results in the production of IgG antibodies directed 
against CII-specific epitopes34. These antibodies have pathogenic potential; however, their levels do not directly 
correlate with disease severity, as high levels can be detected in animals that show no clinical signs of disease35. 
Here, we found that treatment with CDK9 inhibitors or Enbrel had no impact on antibody levels, indicating that B 
cell function remained intact. This finding is interesting when we consider that CDK9 levels change significantly 
during B cell differentiation and activation, and that the expression of CDK9 in memory cells and activated B cells 
is higher than that in naïve cells36.
The anti-inflammatory potential of CDK9 inhibitors is supported by the evidence that CDK9 specifically 
regulates the pro-inflammatory transcription factor, NF-κ B. NF-κ B (p65 subunit) must bind to P-TEFb to induce 
Figure 5. Impact of CDK9 inhibition on mRNA expression. Levels of PNUTS, ID3 and TNF mRNA were 
measured in (A) blood and (B) spleens of arthritic DBA/1 mice at end of experiment and superimposed on 
the levels of inhibitor at the increasing time points following 10 mg/kg PC585 intake (1 h, n = 4; 3 h, n =  3; 
5 h, n = 3). Levels of mRNA of ICAM-1 (C) and VCAM-1 (D) in PBMC pre-incubated with PC585 for 3 h. 
Following incubation compound was washed out (0 h timepoint) and cells were further incubated for up to 24 h.
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transcription-elongation37. Interestingly, gene silencing and treatment with the non-specific CDK inhibitor, fla-
vopiridol, inhibited the recruitment of NF-κ B in human endothelial cells, resulting in a significant reduction in 
ICAM-1 expression, which is crucial for lymphocyte recruitment to inflamed tissues38. Our data confirm these 
results, in vitro experiments revealed that even a short exposure to a CDK9 inhibitor led to a significant reduction 
in the expression of mRNA for ICAM-1 and VCAM-1. Leukocyte migration/extravasation and angiogenesis 
are very important for the pathogenesis of RA39–41; therefore, they are interesting targets for drug development. 
Previous studies suggest that Del-1, which is implicated in angiogenesis, apoptosis, adhesion, migration, and 
proliferation38,42 might be regulated by NF-κ B43. When expressed on the endothelium, Del-1 competes with 
ICAM-1 for binding to LFA-1, thereby inhibiting leukocyte adhesion and subsequent migration through the 
vessel wall. Animal studies show that by inhibiting leukocyte recruitment, Del-1 suppresses both the duration 
and magnitude of the inflammatory response16. Here, we demonstrated that Del-1 expression in the endothelium 
is dependent upon CDK9 and it is tempting to speculate that the regulatory mechanism acts via inactivation of 
NF-κ B. Examination of inflamed joint tissues revealed significant down-regulation of Del-1 expression, which 
was reversed by treatment with a CDK9 inhibitor. It has been shown that Del-1 reduces IL-17-mediated bone 
loss in a periodontitis model by inhibiting IL-17-dependent neutrophil recruitment to inflamed tissues44. Both 
Del-1 and IL-17 are reciprocally cross regulated; indeed, Del-1-mediated down-regulation of IL-17 is one of the 
most important factors that causes cartilage and bone destruction within the joint. Therefore, IL-17 inhibitors 
are an attractive putative RA treatment. The finding that CDK9 inhibitors up-regulate Del-1 expression in joint 
endothelial cells may suggest yet another mechanism that protects against joint inflammation that require further 
investigation.
Material and Methods
Animals. Male DBA/1 (Taconic Europe A/S and Harlan Laboratories) aged 6–8 weeks old were kept under 
standard environmental conditions and had free access to laboratory chow and water. Male DBA/1 mice aged 13 
weeks were used as healthy controls for confocal staining. Experiments were approved by the Animal Research 
Ethical Committee of Gothenburg University, and The UK Home Office and carried out in accordance with the 
approved guidelines.
Induction of Arthritis. Bovine Collagen type II (Chondrex) were emulsified with equal volume of Freund’s 
complete adjuvant and mice were immunized with 100 μ g on day 0 and boosted with 100 μ g CII in Freund’s 
incomplete adjuvant on day 21. When analysing the RNA expression of Pnuts, ID3, TNF and PC585 in blood 
and spleens mice were immunized with 200 μ g Bovine Collagen type II (MD Biosciences) in Freund’s complete 
adjuvant and boosted on day 21 with 200 μ g collagen in PBS i.p, followed by 10 μ g LPS on day 22.
Treatment with CDK9 inhibitors. DBA/1 mice were treated with specific CDK9 inhibitors, PC585 and 
PC579 at 10 mg/kg. The inhibitors were sonicated in 0.8% methyl cellulose (Methocel E4M, Dow) and provided 
to mice through oral gavage. i.p injections of 4 mg/kg Enbrel (etanercept, Wyeth Europe) dosed biweekly was 
used as a reference. Treatment started three days prior induction of arthritis. For the mRNA expression study 
daily treatment with 10 mg/kg of PC585 was initiated at onset of arthritis and sustained for 21 days, until end of 
experiment. Healthy NMRI mice were treated for 7 consecutive days with PC585 to assess the effect of treatment 
on T cell populations.
Clinical evaluation of CIA. Clinical scoring of collagen induced arthritis was performed by an examiner 
blinded and assessed through scoring from 0–3. Swelling and erythema of only a toe or finger was scored as 0.5. 
In the event of culling of an individual mouse the last observed score was carried forward.
Histological evaluation. Hematoxylin and Eosin stained sections were evaluated for synovitis and erosion 
of bone and/or cartilage by a blinded examiner. Joints in knees, ankles, toes, elbows, wrists and fingers were 
scored on a scale from 0–3 (1, mild; 2, moderate; and 3, severe) where half points were allowed. The histological 
score was calculated by dividing the total score per mouse by paws. Occasionally histological sections were not 
possible to score and they were therefore excluded.
Flow cytometric phenotype analysis. Spleens from DBA/1 and NMRI mice were excised and pushed 
through a 70 μ m mesh to obtain a single cell solution. Splenocytes from DBA/1 mice were frozen in 10% DMSO/
FCS until FACS analysis. Cells were pelleted, incubated with Fc-block (anti-CD16/CD32, BD Pharmingen) and 
stained with following antibodies conjugated to either, PE, APC, APC-H7: CD25 (PC61.5, eBioscience) CD19 
(1D3, eBioscience) and CD4 (GK1.5, BD Pharmingen). Following surface stain cells were fixed and permeabilized 
for staining of Foxp3 (FJK-16a, eBioscience) or isotype control (eBR2a, eBioscience). Cells were collected using 
a FACSCantoII equipped with FACSDiva software. Analysis was performed using FlowJo software and fluoro-
chrome minus one (FMO) controls were used for gating when necessary.
Flow cytometric analysis of apoptosis. Human peripheral mononuclear cells (PBMC) were obtained 
by gradient centrifugation on lymphoprep (Axis-shield) and incubated in 37 °C for 12 h with addition of 10 μ M 
PC585 in complete RPMI1640 media. two μ M staurosporine was used as positive control. For further kinetic 
evaluation PBMC was incubated with 10 μ M PC585 for 3 or 6 h in complete RPMI media. Following incubation 
media was replaced and cells were incubated further. Cells were harvested at point of washout (0 h) and additional 
time-points spanning between 12–30 h. The cells were washed with Annexin V binding buffer and stained with 
Annexin V-eFlour 450 and 7AAD (eBioscience) and analysed through flowcytometry. Flow cytometry dot plots 
are shown in Supplementary figure 1.
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Western blot. PBMC were seeded on anti-CD3 (RnD Systems) coated 12-well plate in complete RPMI for 6 
or 24 h in the presence of 10 μ M PC585. PBMC, as well as splenocytes from arthritic mice treated biweekly with 
PC585 and controls, were lysed with RIPA buffer. Samples were resolved on 4–15% Tris-HCl gel (Bio-Rad) and 
transferred to PVDF membrane (Bio-Rad). Following blocking with skim milk membranes were incubated with 
rabbit anti-human/anti-mouse Mcl-1 antibody (Y37, Abcam) as primary and swine anti-rabbit HRP conjugated 
antibody (Dako) as secondary antibody. Mouse anti-rabbit GAPDH (6C5, HyTest) were used as a loading control. 
Blots were developed using ECL detection (Western Blotting Detection Reagents; Amersham Biosciences) and 
images were acquired using Bio-Rad ChemiDoc XRS + system. Adobe Photoshop CS6 was used for post image 
processing.
Quantitative PCR. RNA (0.1 μ g) was reversely transcribed into cDNA using random primers (Roche) and 
Superscript III (Life Technologies). Quantitative PCR was performed in a Rotorgene3000 (Corbett Research) 
using the Rotor-Gene SYBR Green PCR kit (Qiagen) and specific primers for Pnuts, Id3, Mcl1, Icam1, and Vcam 
all synthesized by Metabion (Table 1). Relative amounts of gene expression were determined with the Rotorgene 
software version 6.1 in comparative quantitation mode. Normalization was done against the most stably expressed 
reference gene Ywhaz (NM_011740.2) identified using Normfinder45. The PCR was verified by product melting 
curves and single amplicons were confirmed by agarose gel electrophoresis.
Immunohistochemistry. Joints sections were cut and subjected to antigen retrieval in decloaker chamber 
in Diva Decloaker (Histolab) following deparaffination. Sections were blocked with Protein Block (Dako) for 
30 min before incubation with Rabbit anti-human/anti-mouse Mcl-1 antibody (Y37, abcam). Peroxidase activity 
was blocked with 3% H2O2. Slides were incubated with biotinylated swine anti-rabbit IgG (Dako) and developed 
using ABC detection system with AEC substrate (Vectastain). Sections were counterstained with hematoxylin 
and mounted.
Detection of serum antibodies. Antibodies against CII were detected by coating 96-well plates with 
bovine CII (Chondrex) at the concentration 1 ug/ml. Samples were serial diluted and incubated for 2 h in RT 
following blocking with 0.5% BSA. Secondary antibodies were purchased from Jackson Immunoresearch. Plates 
were developed with TMB substrate reagent set (BD), stopped with 1 M H2SO4 and read at 450 nm.
Confocal microscopy. Sections from mice treated with inhibitor twice weekly were stained with anti-
bodies against mouse Ly6G (RB6-8C5, FITC- conjugate, LifeSpan BioSciences) or with antibodies against 
human/mouse Del-1 (ProteinTech). Where necessary, staining involved the use of a secondary reagent 
(AlexaFluor594-conjugated goat anti-rabbit IgG, Molecular Probes). Images were captured using a laser-scanning 
confocal microscope (Olympus FV1000). Of note, because Del-1 expression decreases with age46, all immuno-
chemical staining was performed on animals of similar age.
Statistical analysis. Statistical differences were performed using two-way ANOVA or one-way ANOVA 
with Bonferroni post-test for multiple comparisons. Kaplan-Meyer graphs were analysed using log-rank test with 
Bonferroni post-test. Mann-Whitney U-test was used for statistical analysis between two groups. All statistical 
analyses were performed using GraphPad Prism, version 5.0d or 6.0b for Mac, a P value of < 0.05 was considered 
statistically significant.
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